The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation

Blood

Volumn 98, Issue 12, 2001, Pages 3192-3204

  Ho, Vincent T ^a   Soiffer, Robert J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALPHA INTERFERON; CYCLOSPORIN; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOTOXIN; INTERFERON; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TUMOR VACCINE;

ACUTE LEUKEMIA; CELLULAR IMMUNITY; CLINICAL TRIAL; CLONAL ANERGY; DONOR; EPSTEIN BARR VIRUS; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; LEUKEMIA REMISSION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOMA; MORTALITY; MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENCE RISK; REVIEW; T LYMPHOCYTE;

EID: 0035760863     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.12.3192     Document Type: Review

References (244)

1. Gale RP, Bortin MM, Van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987;67:396-406.
2. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464-1472.
3. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75:1024-1030.
4. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303-2314.
5. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062-2068.
6. Giralt S, Khouri I, Champlin R. Non myeloablative "mini transplants." Cancer Treat Res. 1999;101:97-108.
7. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80:1838-1845.
8. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
9. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft versus host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267-276.
10. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation: IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000;95:3702-3709.
11. Cutler C, Giri S, Jeyapalan S, et al. Incidence of acute and chronic graft-versus-host disease after allogeneic peripheral blood stem cell and bone marrow transplantation: a meta-analysis [abstract]. Blood. 2000;96:205a.
12. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical bone marrow transplantation. Blood. 1990;75:2459-2464.
13. Ferrera JLM, Antin JH. Pathophysiology of graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Stem Cell Transplantation. Boston, MA: Blackwell Scientific Publications; 1999:305-315.
14. Via CS, Finkelman FD. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol. 1993;5:565-572.
15. Antin J, Weisdorf D, Neuberg D, et al. Interleukin-1 blockade does not prevent acute graft versus host disease (GVHD): results of a randomized double blind, placebo-controlled trial of interleukin 1 receptor antagonist (IL-1 RA) [abstract]. Blood. 1999;94:152a.
16. Antin J, Lee S, Harkness S, et al. Preliminary results of a phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 (rhIL-11) for mucositis and GVHD prevention in allogeneic transplantation [abstract]. Blood. 2000;96:786a.
17. Dicke KA, van Hoot JIM, van Bekkum DW. The selective elimination of immunologically competent cells from bone marrow and lymphatic cell mixtures; II: mouse spleen cell fractionation on a discontinuous albumin gradient. Transplantation. 1968;6:562-570.
18. Reisner Y, Itzicovitch L, Meshorer A, Sharon N. Hematopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. Proc Natl Acad Sci U S A. 1978;75:2933-2936.
19. Trentin JJ, Judd KP. Prevention of acute graft-versus-host (GVH) mortality with spleen-absorbed antithymocyte globulin (ATG). Transplant Proc. 1973;5:865-868.
20. Rodt H, Theirfelder S, Eulitz M. Antilymphocyte antibodies and marrow transplantation; III: effect of heterologous anti-brain antibodies on acute secondary disease in mice. Eur J Immunol. 1974;4:25-29.
21. Rodt H, Thierfelder S, Eulitz M. Antilymphocytic antibodies and marrow transplantation; IV: comparison of the effects of antibody fragments directed against immunoglobulin or lymphocyte antigens on acute secondary disease. Exp Hematol. 1974;2:195-203.
22. Muller-Ruchholtz W, Wottge H-U, Muller-Hermelink HK. Selective grafting of hematopoietic cells. Transplant Proc. 1975;7:859-862.
23. Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice: prevention by removing mature T cells from marrow. J Exp Med. 1978;148:1687-1698.
24. Kolb HJ, Rieder I, Rodt H, et al. Antilymphocyte antibodies and marrow transplantation; VI: graft-versus-host tolerance in DLA-incompatible dogs after in vitro treatment of bone marrow absorbed with antithymocyte globulin. Transplantation. 1979;27:242-245.
25. Rodt H, Kolb HJ, Netzel B, et al. GVHD suppression by incubation of bone marrow grafts with anti-T-cell globulin: effect in canine model and application to clinical bone marrow transplantation. Transplant Proc. 1979;11:962-966.
26. Vallera DA, Soderling CCB, Carlson GJ, Kersey JH. Bone marrow transplantation across major histocompatibility barriers in mice. Transplantation. 1981;31:218-222.
27. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for acute leukemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet. 1981;2:327-331.
28. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatibility parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61:341-348.
29. De Witte T, Hoogenhout J, de Pauw B, et al. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation. Blood. 1986;67:1302-1308.
30. Noga SJ, Donnenberg AD, Schwartz CL, Strauss LC, Civin CI, Santos GB. Development of a simplified counterflow centrifugation elutriation procedure for depletion of lymphocytes from human bone marrow. Transplantation. 1986;41:220-228.
31. Wagner JE, Donnenberg AD, Noga SJ, et al. Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: results of a phase I clinical trial. Blood. 1988;72:1168-1176.
32. Lowenberg B, Wagemaker E, van Bekkum DW, et al. Graft-versus-host disease following transplantation of "one log" versus "two log" T-lymphocyte depleted bone marrow from HLA-identical donors. Bone Marrow Transplant. 1986;1:133-140.
33. Rodt H, Kolb HJ, Netzel B, et al. Effect of anti-T-cell globulin on GVHD in leukemic patients treated with BMT. Transplant Proc. 1981;13:257-261.
34. Prentice HG, Blacklock HA, Janossy G, et al. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft versus host disease in allogeneic bone marrow transplantation for acute leukemia. Lancet. 1982;1:700-703.
35. Filipovich AH, McGlave PB, Ramsay NKC, et al. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft versus host disease in allogeneic histocompatible bone marrow transplantation. Lancet. 1982;1:1266-1269.
36. Martin PJ, Hansen JA, Thomas ED. Preincubation of donor bone marrow cells with a combination of murine monoclonal anti-T-cell antibodies without complement does not prevent graft-versus-host disease after allogeneic marrow transplantation. J Clin Immunol. 1984;4:18-22.
37. Reinherz EL, Geha R, Rappeport JM, et al. Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency. Proc Natl Acad Sci U S A. 1982;79:6047-6051.
38. Gilmore MJML, Prentice HG, Price-Jones E, et al. Allogeneic bone marrow transplantation: the monitoring of granulocyte macrophage colonies following the collection of bone marrow mononuclear cells and after subsequent in-vitro cytolysis of OKT3 positive lymphocytes. Br J Haematol. 1983;55:587-593.
39. Prentice HG, Janossy G, Price-Jones L, et al. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukemic marrow transplant recipients. Lancet. 1984;1:472-475.
40. Waldmann HG, Hale G, Cividalli G, et al. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1). Lancet. 1984;2:483-486.
41. Martin PJ, Hansen JA, Buckner CD, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 1985;66:664-672.
42. Herve P, Flesch M, Cahn JY, et al. Removal of marrow T cells with OKT3-OKT11 monoclonal antibodies and complement to prevent graft-versus-host disease. Transplantation. 1985;39:138-143.
43. Trigg ME, Billing R, Sondel PM, et al. Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants. Cancer Treat Reports. 1985;69:377-386.
44. Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft versus host disease. Ann Intern Med. 1986;105:20-26.
45. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemia. Lancet. 1987;2:175-178.
46. Maraninchi D, Mawas C, Guyotat D, et al. Selective depletion of marrow-T cytotoxic lymphocytes (CD8) in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Transplant Int. 1988;1:91-94.
47. Cahn JY, Herve P, Flesch M, et al. Marrow transplantation from HLA non-identical family donors for the treatment of leukaemias: a pilot study of 15 patients using additional immunosuppression and T-cell depletion. Br J Haematol. 1988;69:345-349.
48. Gabert J, Thuret I, Lafage M, Carcassonne Y, Maraninchi D, Mannoni P. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukaemia patients after bonemarrow transplantation. Lancet. 1989;2:1125-1128.
49. Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992;10:1191-2000.
50. Filipovich AH, Vallera DA, Youle RJ, Neville DM, Kersey JH. Ex vivo T cell depletion with immunotoxins in allogeneic bone marrow transplantation: the pilot clinical study for prevention of graft-versus-host disease. Transplant Proc. 1985;17:442-444.
51. Filipovich AH, Vallera DA, Youle RJ, et al. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. Transplantation. 1987;44:62-69.
52. Laurent G, Maraninchi D, Gluckman E, et al. Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease. Bone Marrow Transplant. 1989;4:367-371.
53. Filipovich AH, Vallera D, McGlave P, et al. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. Transplantation. 1990;50:410-415.
54. Antin JH, Bierer BE, Smith BR, et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood. 1991;78:2139-2149.
55. Vartdal F, Albrechtsen D, Ringden O, et al. Immunomagnetic treatment of bone marrow allografts. Bone Marrow Transplant. 1987;2:94-98.
56. + selection systems or Campath-1. Exp Hematol. 1995;23:147-154.
57. Martin PJ, Hansen JA. Quantitative assays for detection of residual T cells in T-depleted human marrow. Blood. 1985;65:1134-1140.
58. Kernan NA, Flomenberg N, Collins NH, O'Reilly RJ, Dupont B. Quantification of T-lymphocytes in human bone marrow by limiting assay. Transplantation. 1985;40:317-322.
59. Wagner JE, Santos GW, Noga SJ, et al. Bone marrow graft engineering by counterflow elutriation: results of a phase I-II clinical trial. Blood. 1990;75:1370-1377.
60. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186-1193.
61. Hale G, Cobbold S, Waldmann H. T-cell depletion with Campath-1 in allogeneic bone marrow transplantation. Transplantation. 1988;45:753-759.
62. + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood. 1990;76:418-423.
63. Jansen J, Hanks S, Akard L, et al. Selective T cell depletion with CD8-conjugated magnetic beads in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:271-278.
64. + cells for prevention of graft-versus-host disease after bone marrow transplantation: a randomized controlled trial. Transplantation. 1994;57:82-87.
65. - peripheral blood stem cells in patients with advanced hematologic malignancy. Blood. 1996;88:4132-4138.
66. + progenitor cells from matched related donors. Bone Marrow Transplant. 1996;18:1081-1086.
67. - blood cells. Blood. 1996;87:4903-4909.
68. + cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT. Bone Marrow Transplant. 1998;22:519-525.
69. + enrichment by density gradient separation. Bone Marrow Transplant. 2000;25:1223-1228.
70. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 2000;26:69-76.
71. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593-602.
72. Champlin RE, Passweg JR, Zhang MJ, et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000;95:3996-4003.
73. + donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001;19:1152-1159.
74. Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83:1980-1987.
75. Marks DI, Bird JM, Vettenranta K, et al. T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2000;6:646-653.
76. + T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant. 1997;3:11-17.
77. Henslee-Downey PJ, Parrish RS, MacDonald JS, et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation. 1996;61:738-745.
78. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997;89:3864-3872.
79. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84:3948-3955.
80. Soiffer RJ, Dear K, Rabinowe SN, et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991;52:1014-1019.
81. Breuer R, Or R, Lijovetzky G, et al. Interstitial pneumonitis in T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 1988;3:625-630.
82. Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:223-229.
83. Soiffer RJ, Fairelough D, Robertson M, et al. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997;89:3039-3047.
84. Sehn LH, Alyea EP, Weller E, et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999;17:561-568.
85. Drobyski WR, Hessner MJ, Klein JP, et al. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronicphase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood. 1999;94:434-441.
86. Hale G, Zhang MJ, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 1998;92:4581-4590.
87. Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies: results of matched sibling transplants for malignant diseases. Bone Marrow Transplantation. 1994;13:597-611.
88. Novitzky N, Thomas V, Hale G, et al. Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect. Transplantation. 1999;67:620-626.
89. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 1998;91:1083-1090.
90. Beatty PG, Cliff RA, Mickelson EM, et al. Marrow transplantation for related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765-771.
91. Powles RL, Morgenstern GR, Kay HE, et al. Mismatched family donors for bone marrow transplantation as treatment for acute leukemia. Lancet. 1983;1:612-615.
92. Patterson J, Prentice HG, Brenner MK, et al. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol. 1986;63:221-230.
93. O'Reilly R, Collins NH, Kernan N, et al. Transplantation of marrow-depleted T cells by soybean lectin agglutination and E-rosette depletion: major histocompatibility complex-related graft resistance in leukemic transplant patients. Transplant Proc. 1985;17:455.
94. Martin PJ, Hansen JA, Torok-Storb B, et al. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant. 1988;3:437-444.
95. Kernan NA, Bordignon C, Heller G, et al. Graft failure after T-cell-depleted leukocyte antigen identical marrow transplants for leukemia; I: analysis of risk factors and results of secondary transplants. Blood. 1989;74:2227-2236.
96. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73:606-613.
97. Delain M, Cahn JY, Racadot E, et al. Graft failure after T cell depleted HLA identical allogeneic bone marrow transplantation: risk factors in leukemic patients. Leuk Lymphoma. 1993;11:359-368.
98. Herve P, Cahn JG, Flesch M, et al. Successful graft-versus-host disease prevention without graft failure in 32 HLA-identical allogeneic bone marrow transplantations with marrow depleted of T cells by monoclonal antibodies and complement. Blood. 1987;69:388-393.
99. Martin PJ, Hansen JA, Torok-Storb B, et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant. 1988;3:445-456.
100. Marmont A, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78:2120-2130.
101. Guyotat D, Dutou L, Erhsam A, et al. Graft rejection after T cell-depleted marrow transplantation: role of fractionated irradiation. Br J Haematol. 1987;65:499-507.
102. Burnett AK, Hann IM, Robertson AG, et al. Prevention of graft-versus-host disease by ex vivo T cell depletion: reduction in raft failure with augmented total body irradiation. Leukemia. 1988;2:300-303.
103. Sondel PM, Hank JA, Trigg ME, et al, Transplantation of HLA-haploidentical T cell-depleted marrow for leukemia: autologous marrow recovery with specific immune sensitization to donor antigens. Exp Hematol. 1986;14:278-286.
104. Bunjes D, Heit W, Arnold R, et al. Evidence for the involvement of host derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow grafts. Transplantation. 1987;43:501-505.
105. Bunjes D, Theobald M, Wiesneth M, et al. Graft rejection by a population of primed CDw52-host T cells after in vivo/ex vivo T-depleted bone marrow transplantation. Bone Marrow Transplant. 1993;12:209-215.
106. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipients of T cell depleted HLA-nonidentical marrow transplants for leukemia. Transplantation. 1987;43:842-847.
107. Bierer BE, Emerson SG, Antin J, et al. Regulation of cytotoxic T lymphocyte-mediated graft rejection following bone marrow transplantation. Transplantation. 1990;49:714-720.
108. Bordignon C, Keever CA, Small TN, et al. Graft failure after T-cell-depleted leukocyte antigen identical marrow transplants for leukemia; II: in vitro analysis of host effector mechanisms. Blood. 1989;74:2237-2243.
109. Bosserman L, Murray C, Takvorian T, et al. Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bone Marrow Transplant. 1989;4:239-245.
110. Voogt PJ, Fibbe WE, Marjit WA, et al. Rejection of bone marrow graft by recipient derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet. 1990;335:135-144.
111. Fleischauer K, Kernan NA, O'Reilly RJ, Dupont B, Tang SY. Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference on HLA-B44. N Engl J Med. 1990;323:1818-1822.
112. Donohue J, Homge M, Kernan NA. Characterization of cells emerging at the time of graft failure after bone marrow transplantation from an unrelated bone marrow donor. Blood. 1993;82:10231029.
113. Bozdech MJ, Sondel PM, Trigg ME, et al. Transplantation of HLA-haploindentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. Exp Hematol. 1985;13:1201-1210.
114. Gerritsen WR, Wagemaker G, Jonker M, et al. The repopulation capacity of bone marrow grafts following pretreatment with monoclonal antibodies against T lymphocytes in rhesus monkeys. Transplantation. 1988;45:301-307.
115. Anderson KC, Barut BA, Ritz J, et al. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood. 1991;77:712-720.
116. Soiffer RJ, Roy DC, Gonin R, et al. Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant. 1993;12:243-251.
117. Reddehase MJ, Dreher-Stumpp L, Angele P, Balthesen M, Susa M. Hematopoietic stem cell deficiency resulting from cytomegalovirus infection of bone marrow stroma. Ann Hematol. 1992;64(suppl A):125-127.
118. Mutter W, Reddehase MJ, Busch FW, Buhring HJ, Koszinowski UH. Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host. J Exp Med. 1988;67:1645-1658.
119. Steffens HP, Podlech J, Kurz S, Angele P, Dreis D, Reddehase MJ. Cytomegalovirus inhibits the engraftment of donor bone marrow cells by downregulation of hemopoietin gene expression in recipient stroma. J Virol. 1998;72:5006-5015.
120. Johnston RE, Geretti AM, Prentice HG, et al. HHV-6-related secondary graft failure following allogeneic bone marrow transplantation. Br J Haematol. 1999;105:1041-1043.
121. Rosenfeld CS, Rybka WB, Weinbaum D, et al. Late graft failure due to dual bone marrow infection with variants A and B of human herpesvirus-6. Exp Hematol. 1995;23:626-629.
122. Engelhard D, Or R, Strauss N, et al. Cytomegalovirus infection and disease after T cell depleted allogeneic bone marrow transplantation for malignant hematologic diseases. Transplant Proc. 1989;21:3101-3102.
123. Hertenstein B, Hampl W, Bunjes D, et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant. 1995;15:387-393.
124. Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett AJ. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant. 1996;18:347-353.
125. Maltezou H, Whimbey E, Abi-Said D, et al. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study. Bone Marrow Transplant. 1999;24:665-669.
126. Apperley JF, Mauro FR, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol. 1988;69:239-245.
127. Bertheas MF, Lafage M, Levy P, et al. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia. Blood. 1991;78:3103-3106.
128. Offit K, Burns JP, Cunningham I, et al. Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation. Blood. 1990;75:1346-1355.
129. Mackinnon S, Barnett L, O'Reilly R. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83:3409-3416.
130. van Leeuwen JEM, van Tol MJD, Joosten AM, et al. Mixed T-lymphoid chimerism after allogeneic bone marrow transplantation for hematologic malignancies of children is not correlated with relapse. Blood. 1993;82:1921-1928.
131. Butturini A, Seeger RC, Gale RP. Recipient immune-competent T lymphocytes can survive intensive conditioning for bone marrow transplantation. Blood. 1986;68:954-956.
132. Kedar E, Or R, Naparstek E, Zeira E, Slavin S. Preliminary characterization of functional residual host-type T lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT). Bone Marrow Transplant. 1988;3:129-140.
133. Wang W, Meadows LR, den Haan JM, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science. 1995;269:1588-1590.
134. Meadows L, Wang W, den Haan JM, et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity. 1997;6:273-281.
135. Vogt MH, de Paus RA, Voogt PJ, Willemze R, Falkenburg JH. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood. 2000;95:1100-1105.
136. Vogt MH, Goulmy E, Kloosterboer FM, et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood. 2000;96:3126-3132.
137. Cahn JY, Herve P, Flesch M, et al. Marrow transplantation from HLA non-identical family donors for the treatment of leukaemia: a pilot study of 15 patients using additional immunosuppression and T-cell depletion. Br J Haematol. 1988;69:345-349.
138. Ash RC, Casper JT, Chitambar CR, et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med. 1990;322:485-494.
139. Aversa F, Pelicci PG, Terenzi A, et al. Results of T-depleted BMT in chronic myelogenous leukaemia after a conditioning regimen that included thiotepa. Bone Marrow Transplant. 1991;7(suppl 2):24.
140. Schaap N, Schattenberg A, Bar B, et al. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen. Br J Haematol. 1997;98:750-759.
141. Schattenberg A, Schaap N, Preijers F, van der Maazen R, de Witte T. Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients. Bone Marrow Transplant. 2000;26:17-22.
142. Kurisu K, Hishikawa Y, Taniguchi M, et al. Total lymphoid irradiation and total body irradiation for allogeneic bone marrow transplantation in aplastic anemia. Radiat Med. 1991;9:148-152.
143. Castro-Malaspina H, Childs B, Laver J, et al. Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia. Int J Radiat Oncol Biol Phys. 1994;29:847-854.
144. Zapatero A, Marin A, Lopez M, et al. Successful bone marrow transplantation in sensitized aplastic anemia patients using total lymphoid irradiation for conditioning: long-term follow-up. Hematol Oncol. 1996;14:165-172.
145. Soiffer RJ, Mauch P, Tarbell NJ, et al. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant. 1991;7:23-33.
146. + donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001;19:1152-1159.
147. Ganem G, Kuentz M, Beaujean F, et al. Additional total lymphoid irradiation in preventing graft failure of T-cell depleted bone marrow transplantation from HLA-identical siblings. Transplantation. 1987;45:244-248.
148. Cobbold SP, Martin G, Qin S, Waldmann H. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature. 1986;323:164-166.
149. Cobbold S, Martin G, Waldmann H. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection: the depletion of T cell subsets in vitro and in vivo. Transplantation. 1986;42:239-247.
150. Soiffer RJ, Ritz J. Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results. Bone Marrow Transplant. 1993;12(suppl 3):S7-10.
151. + T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998;21:1177-1181.
152. Kawanishi Y, Passweg J, Drobyski WR, et al. Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 1997;19:1069-1077.
153. Poynton CH, Whittaker JA, Bailey-Wood R, et al. Mismatched family and unrelated donors for bone marrow transplantation using fixed low numbers of T cells. Bone Marrow Transplant. 1988;3(suppl 1):223.
154. Potter MN, Pamphilon DH, Cornish JM, Oakhill A. Graft-versus-host disease in children receiving HLA-identical allogeneic bone marrow transplants with a low adjusted T lymphocyte dose. Bone Marrow Transplant. 1991;8:357-361.
155. Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med. 1995;1:1268-1273.
156. Witherspoon RP, Lum LG, Storb R. Immunologic reconstitution after marrow grafting. Sem Hematol. 1984;21:2-10.
157. Mori T, Tsoi MS, Gillis S, Santos E, Thomas ED, Storb R. Cellular interactions in marrow-grafted patients; I: impairment of cell-mediated lympholysis associated with graft-vs-host disease and the effect of interleukin 2. J Immunol. 1983;130:712-716.
158. Brkic S, Tsoi MS, Mori T, et al. Cellular interactions in marrow-grafted patients; III: normal interleukin-1 and defective interleukin-2 production in short-term patients and in those with chronic graft-versus-host disease. Transplantation. 1985;39:30-35.
159. Witherspoon RP, Storb R, Ochs HD, et al. Recovery of antibody production in allogeneic marrow graft recipients: influence of time post transplant, the presence or absence of chronic graft versus host disease, and anti-thymocyte globulin treatment. Blood. 1981;58:360-368.
160. Lum LG, Seigneuret MC, Storb R, et al. In vitro regulation of immunoglobulin synthesis after marrow transplantation, I: T and B cell deficiencies in patients with and without chronic graft versus host disease. Blood. 1981;58:431-439.
161. Witherspoon RP, Lum LG, Storb R, Thomas ED. In vitro regulation of immunoglobulin synthesis after human marrow transplantation; II: deficient T and non-T lymphocyte function within 3-4 months of allogeneic, syngeneic, or autologous marrow grafting for hematologic malignancy. Blood. 1982;59:844-850.
162. Korsmeyer SJ, Elfenbein GJ, Goldman CK, Marshall SL, Santos GW, Waldmann TA. B cell, helper T cell, and suppressor T cell abnormalities contribute to disordered immunoglobulin synthesis in patients following bone marrow transplantation. Transplantation. 1982;33:184-190.
163. Welte K, Keever CA, Levick J, et al. Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation; II: patients receiving soybean lectin-separated and T cell-depleted bone marrow. Blood. 1987;70:1595-1603.
164. Zander AR, Reuben JM, Johnston D, et al. Immune recovery following allogeneic bone marrow transplantation. Transplantation. 1985;40:177-183.
165. Soiffer RJ, Bosserman L, Murray C, Cochran K, Daley J, Ritz J. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood. 1990;75:2076-2084.
166. Pignata C, Sanghera JS, Soiffer RJ, et al. Defective activation of mitogen-activated protein kinase after allogeneic bone marrow transplantation. Blood. 1996;88:2334-2341.
167. Mackall CL, Granger L, Sheard MA, Cepeda R, Gress RE. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood. 1993;82:2585-2594.
168. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995;332:143-149.
169. Pignata C, Gaetaniello L, Masci AM, et al. Human equivalent of the mouse Nude/SCID phenotype: long-term evaluation of immunologic reconstitution after bone marrow transplantation. Blood. 2001;97:880-885.
170. Keever CA, Small TN, Flomenberg N, et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood. 1989;73:1340-1350.
171. Ault KA, Antin JH, Ginsburg D, et al. Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med. 1985;161:1483-1502.
172. Parreira A, Smith J, Hows JM, et al. Immunological reconstitution after bone marrow transplant with Campath-1 treated bone marrow. Clin Exp Immunol. 1987;67:142-150.
173. Roux E, Helg C, Dumont-Girard F, Chapuis B, Jeannet M, Roosnek E. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood. 1996;87:3984-3992.
174. Roux E, Dumont-Girard F, Starobinski M, et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood. 2000;96:2299-2303.
175. Wu CJ, Chillemi A, Alyea EP, et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000;95:352-359.
176. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood. 1988;72:520-529.
177. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71:1234-1243.
178. Gerritsen EJ, Stam ED, Hermans J, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLAidentical BMT in children. Bone Marrow Transplant. 1996;18:377-382.
179. Martin P, Shulman H, Schubach W, et al. Fatal Epstein-Barr virus associated proliferation of donor B-cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Ann Intern Med. 1984;101:310-315.
180. Hanto DW, Najarian JS. Advances in the diagnosis and treatment of EBV-associated lymphoproliferative diseases in immunocompromised hosts. J Surg Oncol. 1985;30:215-220.
181. Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med. 1991;324:1451-1456.
182. Papadapoulos EB, Ladanyl M, Emmanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185-1191.
183. Heslop HE, Brenner MK, Rooney C, et al. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994;5:381-397.
184. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13.
185. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549-1555.
186. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95:807-814.
187. McGuirk JP, Seropian S, Howe G, Smith B, Stoddart L, Cooper DL. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplant. 1999;24:1253-1258.
188. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502-1505.
189. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995;89:98-103.
190. Cavazzana-Calvo M, Bensoussan D, Jabado N, et al. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation. Br J Haematol. 1998;103:543-551.
191. Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depJeted marrow transplants: CAMPATH users. Blood. 1998;91:3079-3083.
192. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806-814.
193. Martin P, Clift RA, Fisher LD, et al. HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. Blood. 1988;72:1978-1984.
194. Marks DI, Hughes TP, Szydlo R, et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. Br J Haematol. 1992;81:383-390.
195. Wagner JE, Zahurak M, Piantadosi S, et al. Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits. J Clin Oncol. 1992;10:779-789.
196. Gratwohl A, Hermans J, Niderwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplantation. 1993;12:509-516.
197. Weiden PL, Flournoy N, Thomas ED, Prentice R, Buckner CD, Storb R. Antileukemic effect of graft-versus-host disease in recipients of allogeneicmarrow grafts. N Engl J Med. 1979;300:1068-1073.
198. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720-1728.
199. Enright H, Davies SM, DeFor T, et al. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective. Blood. 1996;88:714-720.
200. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
201. Collins R, Shpilberg O, Drobyski W, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
202. McGlave P, Bartsch G, Anasetti C, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood. 1993;81:543-550.
203. Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83:1980-1987.
204. Hessner MJ, Endean DJ, Casper JT, et al. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood. 1995;86:3987-3996.
205. Young JW, Papadopoulos EB, Cunningham I, et al. T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood. 1992;79:3380-3387.
206. Bunjes D, Hertenstein B, Wiesneth M, et al. In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate. Bone Marrow Transplant. 1995;5:563-568.
207. Aversa F, Terenzi A, Carotti A, et al. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. J Clin Oncol. 1999;17:1545-1550.
208. Remberger M, Ringden O, Aschan J, Ljungman P, Lonnquist B, Markling L. Long-term follow-up of a randomized trial comparing T-cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients. Transplant Proc. 1994;26:1829-1830.
209. Appelbaum FR, Sullivan KM, Buckner CD, et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol. 1987;5:1340-1347.
210. Shepherd JD, Barnett MJ, Connors JM, et al. Allogeneic bone marrow transplantation for poorprognosis non-Hodgkin's lymphoma. Bone Marrow Transplant. 1993;12:591-596.
211. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649-653.
212. Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol. 1992;10:1690-1695.
213. Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood. 1994;84:1050-1055.
214. Bjorkstrand B, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88:4711-4718.
215. Anderson K, Andersen J, Soiffer R, et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood. 1993;82:2568-2576.
216. Sykes M. Dissociating graft-vs-host disease from the graft-vs-leukemia effect of allogeneic T cells: the potential role of IL-2. Bone Marrow Transplant. 1992;10(suppl 1):1-4.
217. Slavin S, Or R, Prighozina T, et al. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Bone Marrow Transplant. 2000;25(suppl 2):S54-57.
218. Korngold R, Sprent J. T cell subsets and graft versus host disease. Transplantation. 1987;44:335-339.
219. + cells for prevention of graft-versus-host disease after bone marrow transplantation: a randomized controlled trial. Transplantation. 1994;57:82-87.
220. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86:4337-4343.
221. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91:3671-3680.
222. Baker J, Verneris MR, Ito M, et al. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001;97:2923-2931.
223. Mackinnon S, Hows JM, Goldman JM. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood. 1990;76:2037-2045.
224. Hauch M, Gazzola MV, Small T, et al. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood. 1990;75:2250-2262.
225. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333-339.
226. Soiffer RJ, Murray C, Cochran K, et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood. 1992;79:517-526.
227. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood. 1994;84:964-971.
228. Koh MB, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant. 1999;23:1071-1079.
229. Fehse B, Goldmann M, Frerk O, Bulduk M, Zander AR. Depletion of alloreactive donor T cells using immunomagnetic cell selection. Bone Marrow Transplant. 2000;26(suppl 2):S39-42.
230. Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood. 1994;83:3815-3825.
231. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Vallera DA. Co-blockade of the LFA1: ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood. 1995;85:2607-2618.
232. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 1994;84:3261-3282.
233. + T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol. 1997;158:29-39.
234. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340:1704-1714.
235. Alyea E, Weller E, Schlossman R, et al. T cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft versus myeloma effect. Blood. 2001;98:934-939.
236. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
237. Mackinnon S, Papadapoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-1268.
238. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86:4337-4343.
239. Munshi NC, Govindarajan R, Drake R, et al. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood. 1997;89:1334-1340.
240. Link CJ, Burt RK, Traynor AE, et al. Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction: HGTRI 0103. Hum Gene Ther. 1998;9:115-134.
241. Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplex-thymidine kinaseexpressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001;97:63-72.
242. Aubin F, Cahn JY, Ferrand C, Angonin R, Humbert P, Tiberghien P. Extensive vitiligo after ganciclovir treatment of GvHD in a patient who had received donor T cells expressing herpes simplex virus thymidine kinase. Lancet. 2000;355:626-627.
243. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018-1023.
244. Soiffer RJ, Alyea EP, Canning C, et al. Effects of donor lymphocyte infusions (DLI) on prevention of disease relapse after T-cell depleted (TCD) allogeneic bone marrow transplantation (BMT) [abstract]. Blood. In press.